Pfizer (NYSE:PFE) Shares Down 1.9% – Time to Sell?

Pfizer Inc. (NYSE:PFE) traded down 1.9% during trading on Thursday . The stock traded as low as $24.28 and last traded at $24.41. 51,387,826 shares were traded during trading, a decline of 0% from the average session volume of 51,489,281 shares. The stock had previously closed at $24.88.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on PFE shares. Morgan Stanley dropped their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Scotiabank started coverage on shares of Pfizer in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a report on Wednesday, November 5th. Finally, Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.28.

Pfizer Stock Down 1.9%

The firm has a market cap of $138.79 billion, a PE ratio of 12.98, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average price of $24.83 and a two-hundred day moving average price of $24.47.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is presently 100.00%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Westbourne Investments Inc. acquired a new position in Pfizer during the 1st quarter valued at about $2,411,000. Bourne Lent Asset Management Inc. boosted its holdings in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after acquiring an additional 18,200 shares in the last quarter. Strs Ohio acquired a new position in shares of Pfizer during the first quarter valued at approximately $49,968,000. IFM Investors Pty Ltd raised its holdings in Pfizer by 3.8% during the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock worth $27,322,000 after purchasing an additional 41,263 shares in the last quarter. Finally, Intrua Financial LLC raised its holdings in Pfizer by 17.4% during the first quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock worth $1,986,000 after purchasing an additional 11,643 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.